Endometrial cancer and atypical hyperplasia
Conditions
Interventions
Experimental Group:Standard Endometrial Fertility-Preserving Treatment Combined with Tirzepatide Therapy
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.Meets the conditions for fertility-preserving treatment of endometrial lesions (age >=18 years, ,=28 kg/m², or BMI >=24 kg/m² with at least one weight-related comorbidity (such as hypertension, hyperglycemia, sleep apnea syndrome, dyslipidemia, and cardiovascular disease). 4.Able to undergo regular endometrial assessments, body composition analysis, glucose and lipid metabolism evaluations every 3 months during treatment, and regular follow-up after treatment. 5.Non-pregnant at the time of enrollment and agrees to strict contraception during the treatment period.
Exclusion criteria
Exclusion criteria: 1.Concurrent non-reproductive system malignant tumors undergoing treatment. 2.Known rheumatic or autoimmune diseases, active tuberculosis history, hepatitis, HIV infection, or currently receiving hormonal therapy. 3.Liver or kidney dysfunction or active inflammation phase. 4.Pregnancy or lactation period. 5.Participation in other intervention studies. 6.Prior use of other GLP-1 receptor agonist medications before enrollment. 7.Contraindications for the use of GIP/GLP-1 dual receptor agonists (personal or family history of medullary thyroid carcinoma, personal history of multiple endocrine neoplasia syndrome type 2, type 1 diabetes, history of pancreatitis), or allergy to such medications. 8.History of weight loss surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of weight reduction;Reversal of endometrial lesions;Time to reversal of endometrial lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body morphology;Body composition;Glucose and lipid metabolism;Inflammation levels;Incidence of grade 2 or higher adverse events;Incidence of serious adverse events;Pregnancy outcomes;Tumor recurrence; | — |
Countries
China
Contacts
Public ContactJiaxin Yang
Peking Union Medical College Hospital
Outcome results
None listed